Developed market of technology transfer shall be in place to ensure the needs for novel products are met in the Russian pharmaceutical industry – Mikhail Getman

Print 26 March 2013

"Developed market of technology transfer shall be in place to ensure the needs for novel products are met in the Russian pharmaceutical industry”, - said Mikhail Getman, VP for R&D and Regulatory Affairs of NovaMedica, LLC at the 1^st meeting of the Subcommittee for international cooperation in modernization and innovations in healthcare and pharmaceutical industry of the Russian Chamber of Commerce and Trade.

"Moreover it is necessary to develop the licensing market and to generate infrastructure for financial support of new product development at all stages covered, - he continued, - there must be some kind of a bridge between scientists developing new ideas and the industry capable of introducing it. VC firms and funds shall appear to bridge this gap in the country; there is a need to develop an expert review system thorough and cross-sectional focused on the licensing."

Mikhail also noted that now regulatory system shall consider this processes. 

"It is very essential. The fact that the Ministry of Health and Social Development has no differentiating approach in place to pitch for an expert review and registration of new and advanced drugs may severely restrict innovations and prospects because requirements imposed are identical to both primitive replica and disruptive innovations, - M. Getman noticed. -  Also the peer reviews can be problematic. – It makes sense, I suppose, to form ad hoc groups of experts in the Ministry of Health.  There are global foresight-specific research areas, i.e. general self-specific cell technologies, nucleotides are widely speculated in the world, but yet having no common grounds either in FDA and IMA or in the Ministry of Health and Social Development. It is necessary to elaborate a position to comprehend to the field, a signal for innovations”.

M. Getman also noted the introduction of innovations in the medical and pharmaceutical field contradict with an existing approach.

"We scout and invest in advanced novel products arising out of NovaMedica and RMI projects. And note a distinction between medical and pharmaceutical fields, - he explained, - I’ll give you an example – last week we met with the Russian top class spinal surgery specialists to consider value of a new technology and novel type of spinal surgical interventions for the Russian medicine. The question came up: “what is of the most value for a clinic – to have the patient out of the hospital on the same evening after the surgery or to have him in for three more days?". It turns out that today it is more valuable for a medical facility to have the patient in for three days. Therefore, a novel technology, no matter how innovative it is, is considered economically unjustified. These contradictions, however, need to be settled ".

The 1^st meeting of the Subcommittee for international cooperation in modernization and innovations in healthcare and pharmaceutical industry of the Russian Chamber of Commerce and Trade took place on March 26 as part of the InfoSpace Forum for innovative technologies.

The meeting participants have discussed the development of ground-breaking trends in the field considering the international experience and issues related to enhancements in the system of vocational training.

Representatives of the Federation Council, government bodies, scientific, medical and educational leaders, representatives of business enterprises and non-governmental organizations, and international KOLs have been invited to discuss the issues raised. 

Return